A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and Wegovy, is a step toward making them more affordable and accessible ...

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...

The prolonged shutdown has taken a toll on consumer confidence and the overall economy, with consumer sentiment dropping to ...

A man who fainted in the Oval Office last week was a patient of a weight-loss drug company, according to reports.

Access to the obesity medications known as GLP-1 receptor agonists has been a consistent problem for patients because of ...

There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...